1. Harnessing the Immune System: Mechanism of Action of Immunotherapies in B-Cell Malignancies

2. Learning Goals

3. Immunotherapies in B-Cell Malignancies

4. Available Immunotherapies

5. OS in MM

6. Poor Outcome in High-Risk Myeloma

8. Immunotherapy Potential for Success Without a Targetable Molecular Mutation

9. Available Immunotherapies

10. Monoclonal Antibodies Approved for MM

11. Elotuzumab and Daratumumab

12. Daratumumab

13. Elotuzumab

14. Daratumumab Potential MOA

15. Daratumumab Monotherapy Phase 2 Study, ≥ 3 Lines of Prior Therapy

16. Daratumumab in Combination

17. CASTOR Study Daratumumab + Bor/Dex vs Bor/Dex

18. CASTOR Study Efficacy Endpoints and IRRs

19. POLLUX Daratumumab + Len/Dex vs Len/Dex

20. Elotuzumab MOA

21. ELOQUENT-2 Elotuzumab + Len/Dex vs Len/Dex

22. ELOQUENT-2

23. Therapies in Development Antibodies

24. Antibody Drug Conjugates

25. Brentuximab Vedotin

26. AETHERA Brentuximab Vedotin as Consolidation Therapy After ASCT in Patients With HL

27. Other ADCs in Development for MM

28. T-Cell Receptors Activating and Inhibitory

30. Checkpoint Inhibitors in HL

31. Checkpoint Inhibitors in MM

32. Structure of Chimeric Antigen Receptors

33. Clinical Trials With CAR-T Cells in MM

34. CAR-T Cell Therapy

35. Cytokine Release Syndrome (CRS)

36. Response to Tocilizumab in 2 Patients

37. Bispecific T-Cell Engagers

38. Patient-Specific Dendritic Cell/MM Cell Fusion Vaccines Postautologous Transplant

39. Response Rates After Vaccination

40. Future of Immunotherapeutic Strategies in B-Cell Malignancies

41. Conclusions

42. Abbreviations

43. Abbreviations (cont)

44. Abbreviations (cont)

45. Abbreviations (cont)